5-(4-Carbomethoxyphenyl)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,2,4-oxadiazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 5-(4-Carbomethoxyphenyl)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,2,4-oxadiazole
• 英文别名: Methyl 4-[3-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)-1,2,4-oxadiazol-5-yl]benzoate
• 化学式: C₂₄H₂₆N₂O₃
• 分子量: 390.482
• InChiKey: VDFIIGHFXXCNSX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  65.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  potassium carbonate 、 乙醇 、 水 生成 5-(4-Carbomethoxyphenyl)-3-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1,2,4-oxadiazole
  参考文献：
  名称：

  WUEST, HANS-HEINER;JANSSEN, BERND

  摘要：

  DOI：

文献信息

• Diaryl-substituted heterocyclic compounds, drugs and cosmetics obtained
  申请人：BASF Aktiengesellschaft

  公开号：US05061705A1

  公开（公告）日：1991-10-29

  Compounds of formula I ##STR1## wherein R.sup.1 and R.sup.2 are each hydrogen or methyl, A is an ethylene or methylene radical which is unsubstituted or substituted by methyl, hydroxyl or oxo, L is a saturated or unsaturated five-membered or six-membered heterocyclic structure which is unsubstituted or substituted by hydroxyl, mercapto, C.sub.1 -C.sub.6 -alkyl, or C.sub.1 -C.sub.4 -alkanoyl and has from 1 to 3 heteroatoms from the group consisting of N, O and S, the second and third heteroatoms being a nitrogen atom, R.sup.3 is hydrogen, a hydroxy or C.sub.1 -C.sub.6 -alkoxy group, R.sup.4 is hydrogen, C.sub.1 -C.sub.4 -alkyl, halogen or methoxy, R.sup.5 is hydrogen or methoxy or tert-butyl, R.sup.6 is hydrogen, methyl, nitrile or a C.sub.2 -C.sub.10 -ketal group or the radical --CHR.sup.7 OR.sup.8 --CHR.sup.7 --NR.sup.9 R.sup.10, --COR.sup.11, --SR.sup.12, ##STR2## in which R.sup.7 is hydrogen or C.sub.1 -C.sub.4 -alkyl, R.sup.8 is hydrogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.20 -alkanoyl or is benzoyl which is unsubstituted or substituted by methoxy, nitro, methyl or chlorine, R.sup.9 and R.sup.10 are each hydrogen, C.sub.1 -C.sub.4 -alkyl or C.sub.1 -C.sub.6 -alkanoyl or are each benzoyl which is unsubstituted or substituted as for R.sup.8, or R.sup.9 and R.sup.10, together with the nitrogen atom to which they are bonded, form a saturated, 5-membered or 6-membered heterocyclic radical which may contain oxygen as the second heteroatom, R.sup.11 is hydrogen, C.sub.1 -C.sub.4 -alkyl, --OR.sup.13 or --NR.sup.14 R.sup.15, where R.sup.13 is hydrogen, unsubstituted or hydroxyl-substituted C.sub.1 -C.sub.8 -alkyl, aryl or aralkyl which is unsubstituted or substituted by chlorine, bromine, methyl, methoxy or nitro, substitution in the case of the aralkyl group being in the aryl moiety, and where R.sup.14 and R.sup.15 are each hydrogen, unsubstituted or hydroxyl-substituted C.sub.1 -C.sub.6 -alkyl or an aralkyl or aryl group which is unsubstituted or substituted as for R.sup.13, or R.sup.14 and R.sup.15, together with the nitrogen atom to which they are bonded, form a heterocyclic radical as defined above for R.sup.9 and R.sup.10, and R.sup.12 is C.sub.1 -C.sub.4 -alkyl, and compounds of formula Ia ##STR3## where R.sup.3, R.sup.4, R.sup.6 and L have the abovementioned meanings and R.sup.17 is hydrogen or hydroxyl, and their physiologically tolerated salts, processes for their preparation and drugs and cosmetics prepared therefrom.

  式I的化合物其中R.sup.1和R.sup.2分别为氢或甲基，A是未取代或取代为甲基、羟基或氧代的乙烯或亚甲基基团，L是未取代或取代为羟基、巯基、C.sub.1-C.sub.6-烷基或C.sub.1-C.sub.4-醇酰基的饱和或不饱和五元或六元杂环结构，并且其含有1至3个来自N、O和S的杂原子，其中第二和第三个杂原子为氮原子，R.sup.3为氢、羟基或C.sub.1-C.sub.6-烷氧基团，R.sup.4为氢、C.sub.1-C.sub.4-烷基、卤素或甲氧基，R.sup.5为氢、甲氧基或叔丁基，R.sup.6为氢、甲基、腈基或C.sub.2-C.sub.10-糖醚基或基团--CHR.sup.7OR.sup.8--CHR.sup.7--NR.sup.9R.sup.10、--COR.sup.11、--SR.sup.12、其中R.sup.7为氢或C.sub.1-C.sub.4-烷基，R.sup.8为氢、C.sub.1-C.sub.4-烷基或C.sub.1-C.sub.20-醇酰基或未取代或取代为甲氧基、硝基、甲基或氯的苯甲酰基，R.sup.9和R.sup.10分别为氢、C.sub.1-C.sub.4-烷基或C.sub.1-C.sub.6-醇酰基或未取代或取代为R.sup.8的苯甲酰基，或者R.sup.9和R.sup.10连同它们连接的氮原子形成饱和的五元或六元杂环基团，其中可能含有氧作为第二个杂原子，R.sup.11为氢、C.sub.1-C.sub.4-烷基、--OR.sup.13或--NR.sup.14R.sup.15，其中R.sup.13为氢、未取代或羟基取代的C.sub.1-C.sub.8-烷基、芳基或芳基烷基，其未取代或取代为氯、溴、甲基、甲氧基或硝基，芳基烷基组的取代在芳基部分，R.sup.14和R.sup.15分别为氢、未取代或羟基取代的C.sub.1-C.sub.6-烷基或未取代或取代为R.sup.13的芳基烷基或芳基基团，或者R.sup.14和R.sup.15连同它们连接的氮原子形成如上所定义的R.sup.9和R.sup.10的杂环基团，R.sup.12为C.sub.1-C.sub.4-烷基，以及式Ia的化合物其中R.sup.3、R.sup.4、R.sup.6和L具有上述含义，R.sup.17为氢或羟基，以及其生理耐受盐、其制备方法以及由此制备的药物和化妆品。
• WUEST, HANS-HEINER;JANSSEN, BERND
  作者：WUEST, HANS-HEINER、JANSSEN, BERND

  DOI：——

  日期：——
• Diarylsubstituierte heterocyclische Verbindung, ihre Herstellung und Arzneimittel und Kosmetika daraus
  申请人：BASF Aktiengesellschaft

  公开号：EP0382077B1

  公开（公告）日：1995-05-17
• USE OR RETINOIDS TO LOWER PLASMA LEVELS OF LIPOPROTEIN (a)
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0808159A1

  公开（公告）日：1997-11-26
• US5061705A
  申请人：——

  公开号：US5061705A

  公开（公告）日：1991-10-29